GlassScriptPhysician profile
Christine Herdman
NPI 1487783767
$7,422.72
in general payments reported to CMS, 2019-2025
32 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $271 · 2021: $540 · 2022: $785 · 2023: $1,240 · 2024: $1,688 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,951.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,055.21 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $870.20 | 2019-2025 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $652.07 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $437.81 | 2019-2025 | Entyvio, Gattex |
| Regeneron Healthcare Solutions, INC. | $324.70 | 2023-2025 | Dupixent |
| Genzyme Corporation | $273.39 | 2023-2025 | |
| Ardelyx, INC. | $270.32 | 2023-2025 | Ibsrela |
| Pfizer INC. | $172.30 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $161.29 | 2019-2024 | Linzess |
| Gilead Sciences, INC. | $155.71 | 2019-2025 | |
| Madrigal Pharmaceuticals | $155.33 | 2025 | Rezdiffra |
| Qol Medical, LLC | $122.79 | 2019-2024 | Sucraid |
| Lilly USA, LLC | $104.52 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $86.18 | 2023-2024 | Rebyota |
| Amgen INC. | $80.22 | 2025 | Uplizna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $76.53 | 2023-2024 | Zeposia |
| Novo Nordisk INC | $51.51 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $40.40 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $38.67 | 2025 | Voquezna |
| Biofire Diagnostics, LLC | $37.68 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $36.70 | 2024-2025 | Rapide Balloons, Lesionhunter |
| Fresenius Kabi USA, LLC | $35.85 | 2023-2024 | Idacio |
| Aimmune Therapeutics, INC. | $27.91 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $26.02 | 2024 | Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.54 | 2024 | Cyltezo |
| Sandoz INC. | $17.48 | 2023 | Hyrimoz |
| Evoke Pharma, INC. | $16.88 | 2024 | |
| Merck Sharp & Dohme LLC | $16.29 | 2023 | Dificid |
| Covidien LP | $16.06 | 2019 | |
| Shionogi INC | $15.65 | 2020 | |
| Amag Pharmaceuticals, INC. | $12.63 | 2019 | |
| Allergan, INC. | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Herdman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.